Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (109)

II-001Katharina Braun

Prospective randomised controlled trial on model-informed precision dosing (MIPD) for ustekinumab and vedolizumab in inflammatory bowel diseases (MOVE-IT): A Bayesian framework incorporating parameter uncertainty

Wed, Jun 3, 2026 3:20PM–4:50PM

II-002Cleo Demeester

BUILDING AN OPEN-SOURCE SUB-SAHARAN AFRICAN PBPK POPULATION: INTEGRATING ANATOMICAL, PHYSIOLOGICAL, AND ENZYMATIC VARIABILITY

Wed, Jun 3, 2026 3:20PM–4:50PM

II-003Omnia S. Heikal

Modeling of Vancomycin-Induced Changes in Serum Creatinine to Improve Prediction of Acute Kidney Injury

Wed, Jun 3, 2026 3:20PM–4:50PM

II-004Nandawula Habra

Exposure Comparison of Standard Versus Alternate Hydroxyurea Dosing in Ugandan Children with Sickle Cell Disease: A Non-Compartmental Pharmacokinetic Analysis

Wed, Jun 3, 2026 15:20PM–16:50PM

II-005Venkatesh Pilla Reddy

Translational PK/PD modelling of sofetabart mipitecan, an antibody-drug conjugate linked to exatecan via a novel cleavable polysarcosine linker

Wed, Jun 3, 2026 3:20PM–4:50PM

II-006Carlos Serra Traynor

KPD-ML PREDICTION OF DOCETAXEL‑INDUCED NEUTROPENIA IN LARGE RWE DATASETS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-007Zhiyuan Tan

Characterization of real-world pembrolizumab population pharmacokinetics in cancer patients: towards identification of non-responders using change in clearance as efficacy biomarker and individualization of the dosing interval

Wed, Jun 3, 2026 3:20PM–4:50PM

II-008Zhiheng Yu

Does Nonlinear Absorption of Oral Misoprostol Challenge Guideline-Based Dosing in Late Pregnancy Cervical Ripening? A Population Pharmacokinetic Model to Resolve.

Wed, Jun 3, 2026 3:20PM–4:50PM

II-009Jose M Calderin

POPULATION PHARMACOKINETIC MODELLING OF BEDAQUILINE IN CENTRAL NERVOUS SYSTEM TISSUES IN A RABBIT MODEL OF TUBERCULOUS MENINGITIS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-010Ruben Faelens

Predicting Total Immunoglobulin G When Switching From Efgartigimod To Nipocalimab

Wed, Jun 3, 2026 3:20PM–4:50PM

II-011Karsten Kuritz

EXPOSURE-RESPONSE MODELING OF PANSS IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH SUBCUTANEOUS OLANZAPINE LAI (TV-44749) WITH A JOINT DROPOUT MODEL

Wed, Jun 3, 2026 3:20PM–4:50PM

II-012Marie Alexandre

Joint mechanistic modeling of viral and antibody responses to vaccines in Non-Human Primates to quantify SARS-CoV-2 mechanistic correlate of protection.

Wed, Jun 3, 2026 3:20PM–4:50PM

II-013Maxime Beaulieu

The analysis of a large dataset of PCR-test results in the community reveals the impact of age, variants and vaccination status on SARS-CoV-2 viral dynamics

Wed, Jun 3, 2026 3:20PM–4:50PM

II-014Clémence Boivin-champeaux

A multi-compartment QSP model of hepatitis B infection linking viral life cycle and immune regulation to support model-informed therapy evaluation

Wed, Jun 3, 2026 3:20PM–4:50PM

II-015Ibrahim El-haffaf

Exploring the impact of extracorporeal membrane oxygenation (ECMO) therapy on piperacillin pharmacokinetics: do general intensive care unit models perform similarly to ECMO models?

Wed, Jun 3, 2026 3:20PM–4:50PM

II-016Jaegu Kang

Population Pharmacokinetic Modeling of Vancomycin in Ventricular Assist Device Implanted Patients: Exploration for Role of Hemodynamic Parameters

Wed, Jun 3, 2026 3:20PM–4:50PM

II-017Jessica Lee

TRANSLATIONAL PKPD MODELLING FRAMEWORK TO SUPPORT PRIORITISATION OF NOVEL TUBERCULOSIS REGIMENS WITHIN THE PARADIGM4TB PLATFORM.

Wed, Jun 3, 2026 3:20PM–4:50PM

II-018Rentia Lourens

POPULATION PHARMACOKINETICS AND PHARMACOGENOMICS OF ETHAMBUTOL IN AN AFRICAN COHORT WITH DRUG RESISTANT PULMONARY TUBERCULOSIS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-019Andrés Mazariegos Herrera

An individual patient data meta-analysis of miltefosine pharmacokinetics across clinical forms of leishmaniasis

Wed, Jun 3, 2026 3:20PM–4:50PM

II-020Thi Minh Nguyet Nguyen

Modelling pharmacokinetic-pharmacodynamic of PBTZ169 in glycerol and cholesterol using CFU and MPN as biomarkers

Wed, Jun 3, 2026 3:20PM–4:50PM

II-021Michael Jacques Rossouw

EFFECT OF METFORMIN ON THE PHARMACOKINETICS OF RIFAMPICIN, ISONIAZID, AND PYRAZINAMIDE IN ADULTS WITH TB AND HIV

Wed, Jun 3, 2026 3:20PM–4:50PM

II-022Ruben van de Venter

Population Pharmacokinetics of Dolutegravir with Daily Rifapentine for HIV-associated Tuberculosis

Wed, Jun 3, 2026 3:20PM–4:50PM

II-023Alberto Vegas Rodriguez

Development of an In-Silico Platform to Explore HIV Incidence Across Different Regions and Its Application to PrEP Clinical Trials for Treatment Design and Optimization

Wed, Jun 3, 2026 3:20PM–4:50PM

II-024Tan Zhang

Population pharmacokinetic–based probability of target attainment analysis of cefepime/nacubactam and aztreonam/nacubactam for carbapenem-resistant enterobacterales infections

Wed, Jun 3, 2026 3:20PM–4:50PM

II-025Ahmed Atta

Mechanistic Modeling of Radiation-Induced Immune Responses in Normal Lung Tissue

Wed, Jun 3, 2026 3:20PM–4:50PM

II-026Fabian Cardozo

PRECURSOR-POOL MODEL OF CYTOKINE KINETICS IN PATIENTS RECEIVING LINVOSELTAMAB

Wed, Jun 3, 2026 3:20PM–4:50PM

II-027Suthunya Chupradit

POPULATION PHARMACOKINETICS OF MYCOPHENOLIC ACID IN PATIENTS WITH HIGH-GRADE LOCALLY ADVANCED OR METASTATIC OSTEOSARCOMA

Wed, Jun 3, 2026 3:20PM–4:50PM

II-028Lola FÉRÉ GELY

Mechanistic–Latent Class Modeling to Improve Response Classification in «Mouse Clinical Trials»

Wed, Jun 3, 2026 3:20PM–4:50PM

II-029Masato Fukae

APPLICATION OF DEEPNLME FRAMEWORK TO CHARACTERIZE DISTINCT PLATELET DYNAMICS IN PATIENTS TREATED WITH MILADEMETAN

Wed, Jun 3, 2026 3:20PM–4:50PM

II-030Eva Helmer

INFLUENCE OF NON-ADHERENCE ON THE ESTIMATION OF PHARMACOKINETIC PARAMETERS OF CABOZANTINIB IN RENAL CELL CARCINOMA

Wed, Jun 3, 2026 3:20PM–4:50PM

II-031Frederic Lusoli

Using deconvolution to support the development of an abemaciclib parent-metabolite joint pharmacokinetic model

Wed, Jun 3, 2026 3:20PM–4:50PM

II-032Anna Mc Laughlin

A MECHANISM-BASED PARSIMONIOUS CAR-T CELL POPULATION PK MODEL AND ITS VALIDATION VIA EXTENSION TO A POPULATION PK-TUMOR SIZE DYNAMICS MODEL: CASE STUDY WITH AXICABTAGENE CILOLEUCEL AND BREXUCABTAGENE AUTOLEUCEL

Wed, Jun 3, 2026 3:20PM–4:50PM

II-033Anna-Kristina Oma

Population pharmacokinetics supports pembrolizumab de-escalation while meeting target exposure in advanced non-small cell lung cancer

Wed, Jun 3, 2026 3:20PM–4:50PM

II-034Ruediger E. Port

MIXED-EFFECTS MODELING OF THE PLASMA KINETICS OF THE ANTI-CD8 PET TRACER [18F]-2C8v144 AND THE NON-BINDING CONTROL TRACER [18F]-2C8V145 ENABLES ESTIMATES OF THE TOTAL AMOUNT OF CD8 IN THE BODY AND THE FRACTION PRESENT IN BLOOD, AND THE EQUILIBRIUM DISSOCIATION CONSTANT (K_D) OF [18F]-2C8v144; AND PREDICTIONS OF TOTAL BODY RECEPTOR OCCUPANCY BY [18F]-2C8v144

Wed, Jun 3, 2026 3:20PM–4:50PM

II-035Dmitry Shchelokov

Quantitative Systems Pharmacology Modeling to Explore Alternative Step-Up Dosing Regimens for Tarlatamab, a DLL3-Targeting T-Cell Engager

Wed, Jun 3, 2026 3:20PM–4:50PM

II-036Hoai-Thu Thai

Isatuximab SC versus IV in patients with Relapsed/Refractory Multiple Myeloma: Insights from longitudinal PK/PD Analysis of Serum M-Protein in the non-inferiority IRAKLIA Trial

Wed, Jun 3, 2026 3:20PM–4:50PM

II-037Areti-Maria Vasilogianni

Cancer-Driven Changes in Small Intestinal and Colonic Drug-Metabolising Enzymes and Transporters: Updating Cancer Populations for PBPK Modelling and Pharmacokinetic Implications

Wed, Jun 3, 2026 3:20PM–4:50PM

II-038Romain Zakrajsek

Mechanistic modeling of the natural history of cancer progression and metastatic dissemination in stage I non-small cell lung cancer patients after curative surgery

Wed, Jun 3, 2026 3:20PM–4:50PM

II-039Md Almomin

QUANTITATIVE DIFFERENCES IN TRENDS OF INFLAMMATORY BIOMARKERS IN PREGNANT AND POSTPARTUM INDIVIDUALS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE

Wed, Jun 3, 2026 3:20PM–4:50PM

II-040Noah Brostoff

Enrichment, Response Amplification, Separation, and Inclusion: Quantifying Trial Design Trade-offs in SLE with QSP SimPops™ Modeling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-041Huong Tra Dang

Model-based meta-analysis of CGRP antagonists for migraine: A comprehensive evaluation of efficacy and dose-response modelling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-042Alan Faraj

Population pharmacokinetics of an oral combination of decitabine and tetrahydrouridine in healthy volunteers

Wed, Jun 3, 2026 3:20PM–4:50PM

II-043Ana Homšek

Predicting Mucosal Healing in IBD: The Interplay of Platelet Levels and Infliximab Pharmacokinetics

Wed, Jun 3, 2026 3:20PM–4:50PM

II-044Seongwook Jeong

PHARMACODYNAMIC COMPARISON OF THE ADMS INDEX AND BIS DURING SEVOFLURANE ANESTHESIA: CONCENTRATION–EFFECT MODELING, AGREEMENT, AND DYNAMIC PERFORMANCE

Wed, Jun 3, 2026 3:20PM–4:50PM

II-045Victoria Kulesh

Quantitative Systems Immunology: Unraveling Human CD4+ T-Lymphocyte Kinetics, Tissue Distribution, and Aging Using Mechanistic Modeling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-046Rocio Lledo Garcia

MODEL-INFORMED FIXED DOSING OF ROZANOLIXIZUMAB IN gMG: PK/PD ADVANTAGES AND COMPARISON FROM OTHER FcRn BLOCKERS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-047Giulia Monchietto

Initialising a structured framework to generate virtual patient cohorts in support of drug development in rare and pediatric diseases: Collating and developing methodological modelling and simulation techniques under scenarios of limited knowledge availability

Wed, Jun 3, 2026 3:20PM–4:50PM

II-048Neelima Patnaikuni

QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODELING OF EFFICACY AND NAUSEA OF GLP-1 RECEPTOR AGONIST (RA) SEMAGLUTIDE AND DUAL GLP-1/GIPRA TIRZEPATIDE IN NON-DIABETIC OBESE PATIENTS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-049Sebastian Polak

Development and application of ML based drug renal clearance predictor

Wed, Jun 3, 2026 3:20PM–4:50PM

II-050Clarisse Schumer

Automated model selection for within-host viral dynamics of SARS-CoV-2 and IAV

Wed, Jun 3, 2026 3:20PM–4:50PM

II-051Flávia Teixeira

Population pharmacokinetic modeling to characterize the exposure of LASSBio-1736 in rats

Wed, Jun 3, 2026 3:20PM–4:50PM

II-052Sven van Dijkman

Design and implementation of a model-optimised paroxetine C-QT study

Wed, Jun 3, 2026 3:20PM–4:50PM

II-053Katarina Vučićević

A Population Pharmacokinetic Framework for Adalimumab TDM in Crohn’s Disease

Wed, Jun 3, 2026 3:20PM–4:50PM

II-054Jessica Wojciechowski

INTEGRATED MIXED EFFECTS ANALYSIS OF PHARMACOKINETICS OF RUXOLITINIB CREAM AND IMPLICATIONS ON ITS SAFETY PROFILE IN ADULT PATIENTS WITH ATOPIC DERMATITIS OR VITILIGO

Wed, Jun 3, 2026 3:20PM–4:50PM

II-055Chiara Zecchin

MODEL-BASED META-ANALYSIS TO INFORM CHRONIC KIDNEY DISEASE DRUG DEVELOPMENT

Wed, Jun 3, 2026 3:20PM–4:50PM

II-056Zrinka Duvnjak

Should models for model-informed precision dosing (MIPD) purposes be full random-effects models (FREM) when a covariate is missing?

Wed, Jun 3, 2026 3:20PM–4:50PM

II-057Joakim Nyberg

The use of Full Random Effect Models (FREM) in Model Informed Precision Dosing (MIPD) for a priori dose predictions

Wed, Jun 3, 2026 3:20PM–4:50PM

II-058Kunal Anilkumar

Challenges in Generating a Ground Truth for Method Development in Model-Informed Precision Dosing

Wed, Jun 3, 2026 3:20PM–4:50PM

II-059Andreas Noack

New benchmarks for FOCE

Wed, Jun 3, 2026 3:20PM–4:50PM

II-060Vincent Chang

Predicting Receptor Occupancy via Empirical Approximations from Nonlinear Population PK Modeling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-061Ron Keizer

Visual Predictive Checks for Real-World Data using Propensity-Score-Matching

Wed, Jun 3, 2026 3:20PM–4:50PM

II-062Veronika Alberg

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF LOSARTAN FOR THE PREDICTION OF DRUG-DRUG- AND DRUG-GENE-INTERACTIONS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-063Lisa Cheng

THE CRITICAL ROLE OF GASTRIC REACIDIFICATION IN PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELS INVESTIGATING FOOD EFFECT: A CASE STUDY WITH PICTILISIB

Wed, Jun 3, 2026 3:20PM–4:50PM

II-064Dorota Danielak

LEVERAGING SEMI-MECHANISTIC PHARMACOKINETIC MODELING TO ESTABLISH CLINICALLY RELEVANT DISSOLUTION SAFE SPACES IN COMPASS SOFTWARE

Wed, Jun 3, 2026 3:20PM–4:50PM

II-065Henry Enzama

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR SUB-SAHARAN AFRICAN POPULATIONS: A REVIEW OF SYSTEM PARAMETERS AND VARIABILITY DRIVERS.

Wed, Jun 3, 2026 15:20PM–16:50PM

II-066Justine Henriot

PRECLINICAL PBPK MODELING FOR PERSONALIZED THERAPY AND DOTA-TATE-BASED RADIOPHARMACEUTICAL MODULARITY

Wed, Jun 3, 2026 3:20PM–4:50PM

II-067Helene Kenter

Accounting for Cell Settling Is Critical for Accurate In Vitro Trimer Formation Modeling of T Cell Engagers

Wed, Jun 3, 2026 3:20PM–4:50PM

II-068Panos Macheras

Finite Pharmacokinetics (FTPK) software: Strategic Acceleration of Oral Drug Development via Single-Point IV Pharmacokinetic Profiling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-069Mariia Myshkina

PK-DB 2.0: An Open Pharmacokinetics and Pharmacodynamics Database for Pharmacometric Modeling, AI, and Digital Twins

Wed, Jun 3, 2026 3:20PM–4:50PM

II-070Marta Rodríguez Jiménez

A semi-mechanistic model for tumor regression effects of IL-2 receptor-targeted nanocarrires modulating Treg activity

Wed, Jun 3, 2026 3:20PM–4:50PM

II-071Nadia Toffoletto

DEVELOPMENT OF A GENERAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF DRUG DISTRIBUTION AFTER PERIOCULAR ADMINISTRATION

Wed, Jun 3, 2026 3:20PM–4:50PM

II-072Hyunju Yang

DEVELOPMENT OF NASAL PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR NICLOSAMIDE TO QUANTIFY NASAL MUCOSA EXPOSURE

Wed, Jun 3, 2026 3:20PM–4:50PM

II-073Hanna Kunina

LONGITUDINAL MODELLING OF CARDIOMETABOLIC DYSFUNCTION IN PATIENTS WITH TYPE 2 DIABETES USING ITEM RESPONSE THEORY

Wed, Jun 3, 2026 3:20PM–4:50PM

II-074Raphaela Schenk

Vicadrostat Pharmacodynamics and steroidogenesis validated and explained: A mechanistic QSP model

Wed, Jun 3, 2026 3:20PM–4:50PM

II-075Sally Babiker

Model-informed extrapolation of pyrazinamide brain exposure in children with tuberculous meningitis

Wed, Jun 3, 2026 3:20PM–4:50PM

II-076Salomé Dumasdelage

Systemic bioavailability and cortisol suppression of ocular dexamethasone in preterm infants: a PK/PD analysis

Wed, Jun 3, 2026 3:20PM–4:50PM

II-077Laura Ibarra Gomez

Model-informed approach to Support Dose Selection for Lurbinectedin in Pediatric Patients with Advanced Solid Tumors and Recurrent/Refractory Ewing Sarcoma

Wed, Jun 3, 2026 3:20PM–4:50PM

II-078Orestis Papatryfonos

MODEL-BASED META-ANALYSIS OF PARACETAMOL DOSE–RESPONSE IN PAEDIATRIC TONSILLECTOMY PAIN

Wed, Jun 3, 2026 3:20PM–4:50PM

II-079Aymara Sancho-Araiz

Quantifying the CYP3A ontogeny in the gut wall and liver using a reduced population physiologically-based pharmacokinetic model

Wed, Jun 3, 2026 3:20PM–4:50PM

II-080Jen-Hao (Eric) Wu

Population pharmacokinetic analysis of etoposide and model-based dosing evaluation in pediatric oncology

Wed, Jun 3, 2026 3:20PM–4:50PM

II-081Geraldine Celliere

Handling Hysteresis in Concentration–QTc Analysis: A PK/PD Effect-Compartment Approach Illustrated with Vanoxerine

Wed, Jun 3, 2026 3:20PM–4:50PM

II-082Klaus Lindauer

Concentration-QTc (C-QTc) analysis using PK/PD modeling to evaluate time- and exposure-dependent drug-induced QT interval prolongation

Wed, Jun 3, 2026 3:20PM–4:50PM

II-083Johannes Tillil

Model-based assessment of the prothrombin time test during transition from rivaroxaban to warfarin

Wed, Jun 3, 2026 3:20PM–4:50PM

II-084Lara Carter

Homoscedastic Uncertainty Weighting-Enhanced Multi-Task Multi-Granularity NER for Pharmacokinetic Parameters

Wed, Jun 3, 2026 3:20PM–4:50PM

II-085Sungwoo Goo

Interpretable Deep Learning Survival Analysis of Alzheimer’s Disease Using Genetic Variants Associated with Metabolic Disorders

Wed, Jun 3, 2026 3:20PM–4:50PM

II-086Julian Kurz

MULTI-AGENT AI APPLICATION FOR INTERACTIVE EXPLORATORY CLINICAL DATA ANALYSIS IN R

Wed, Jun 3, 2026 3:20PM–4:50PM

II-087Benjamin Maurel

Latent Neural-ODE for Model-Informed Precision Dosing: Overcoming Structural Assumptions in Pharmacokinetics

Wed, Jun 3, 2026 3:20PM–4:50PM

II-088César Ali Ojeda Marin

PRIOR-FITTED AMORTIZED GENERATIVE NEURAL NETWORKS MODELS FOR POPULATION PHARMACOKINETICS

Wed, Jun 3, 2026 15:20PM–16:50PM

II-088Yorgos M. Psarellis

Preclinical and clinical pharmacokinetic prediction via Machine Learning

Wed, Jun 3, 2026 3:20PM–4:50PM

II-089Elba Raimúndez

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Wed, Jun 3, 2026 3:20PM–4:50PM

II-090Felix Hammann

Machine learning for covariate imputation – application in a real-world scenario

Wed, Jun 3, 2026 3:20PM–4:50PM

II-091Marcus Baaz

The Empirical Bayes Variational Autoencoder – A Neural ODE Approach for Population Modeling in Pharmacology

Wed, Jun 3, 2026 3:20PM–4:50PM

II-092Emmanuelle Comets

A novel workflow integrating PET microdosing data and therapeutic-dose pharmacokinetics across species to inform first-in-human dose selection

Wed, Jun 3, 2026 3:20PM–4:50PM

II-093Zhonghui Huang

A framework for nlmixr2auto: an open-source R package on CRAN for automated population pharmacokinetic modelling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-094Anna Largajolli

Combining aggregate data and individual patient/subject data in model-based meta-analysis: An illustrative case study of tofacitinib in rheumatoid arthritis patients

Wed, Jun 3, 2026 3:20PM–4:50PM

II-095Luca Marzano

IMPROVING CLINICAL DATA HARMONIZATION FOR POPULATION APPROACHES USING GRAPH DATABASES

Wed, Jun 3, 2026 3:20PM–4:50PM

II-096Matthias Pierre

COMPARISON OF MACHINE LEARNING ALGORITHMS FOR RAPID COMPARTMENTAL MDOEL SELECTION

Wed, Jun 3, 2026 3:20PM–4:50PM

II-097Darian Schirr

Mechanistic PK/PD Modeling Framework for Targeted Covalent Inhibitors: Applications to Guide Lead Optimization, Inform Study Design, and Predict in vivo Efficacy

Wed, Jun 3, 2026 3:20PM–4:50PM

II-098Anitha Suram

A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL LINKING KIT SIGNALING TO MAST CELL DEGRANULATION AND DEPLETION

Wed, Jun 3, 2026 3:20PM–4:50PM

II-099Gustaf Wellhagen

BOUNDED INTEGER MODELING OF NEUROPATHY, QUALITY OF LIFE AND ACUTE ADVERSE EVENT SCALES IN PATIENTS WITH COLORECTAL CANCER

Wed, Jun 3, 2026 3:20PM–4:50PM

II-100Muriel Boulton

Choosing the Right Exposure Metric: Power and Confounding in Exposure-Response (E-R) Models

Wed, Jun 3, 2026 3:20PM–4:50PM

II-101Ari Brekkan

Use the AUC and discard Cmax in exposure-response analysis

Wed, Jun 3, 2026 3:20PM–4:50PM

II-102Meemansa Sood

Enhancing Data Sharing and Anonymization to Enable Model-Based Approaches and Virtual Patient Cohorts in the INVENTS Project

Wed, Jun 3, 2026 3:20PM–4:50PM

II-103Elodie Valade

Impact of Below Limit of Quantification (BLQ) Concentrations handling strategies on Concentration-QTc analysis

Wed, Jun 3, 2026 3:20PM–4:50PM

II-104Kohei Yamaguchi

METHODS FOR SUBGROUP SIMILARITY ASSESSMENT IN DOSE-RESPONSE META-ANALYSIS USING A BOOTSTRAP APPROACH

Wed, Jun 3, 2026 3:20PM–4:50PM

II-105Manuela Zimmermann

A POTENTIAL COST OF BLOCK-DIAGONAL Ω:
BIASED DOSE-RESPONSE ESTIMATES IN THE PRESENCE OF EXPOSURE-RESPONSE CONFOUNDING

Wed, Jun 3, 2026 3:20PM–4:50PM

II-106Helene Haguet

MODEL-BASED META-ANALYSIS POPULATION PK MODELING OF ANTI-IL-5(RΑ) MONOCLONAL ANTIBODIES TO OPTIMIZE PEDIATRIC STUDY DESIGN USING STOCHASTIC SIMULATION-ESTIMATION

Wed, Jun 3, 2026 3:20PM–4:50PM

II-107Anaëlle Monfort

A Pharmacokinetic-Based Decision Tree to Guide Methods Selection for Safety Evaluation of Infant Systemic Exposure through Human Milk

Wed, Jun 3, 2026 3:20PM–4:50PM

II-108Monika Twarogowska

Model-Informed Biosimilar Study Design Under Evolving Regulatory Guidance: Dose Selection and Power Optimization in Pegfilgrastim

Wed, Jun 3, 2026 3:20PM–4:50PM